Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

(2022) Sai-Hong Ignatius Ou et al.   JOURNAL OF CLINICAL ONCOLOGY

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer

(2022) Marwan Fakih et al.   ONCOLOGIST

Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.

(2022) Joel W. Neal et al.   JOURNAL OF CLINICAL ONCOLOGY

KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy

(2022) Meagan B. Ryan et al.   Cell Reports

Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type

(2021) Amin H. Nassar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

(2021) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhancing the landscape of colorectal cancer using targeted deep sequencing

(2021) Chul Seung Lee et al.   Scientific Reports

Acquired Resistance to KRASG12C Inhibition in Cancer

(2021) Mark M. Awad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Strategies to tackle RAS-mutated metastatic colorectal cancer

(2021) G. Patelli et al.   ESMO Open

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

(2021) Marwan G Fakih et al.   LANCET ONCOLOGY

KRAS G12C metastatic colorectal cancer: specific features of a new emerging target population

(2020) Marta Schirripa et al.   Clinical Colorectal Cancer

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

(2020) Jay B. Fell et al.   JOURNAL OF MEDICINAL CHEMISTRY

EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer

(2020) Vito Amodio et al.   Cancer Discovery

Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment

(2020) Marloes Zoetemelk et al.   MOLECULES

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

(2020) David S. Hong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the untargetable KRAS in cancer therapy

(2019) Pingyu Liu et al.   Acta Pharmaceutica Sinica B

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

(2019) Scott Kopetz et al.   NEW ENGLAND JOURNAL OF MEDICINE

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

(2019) Jill Hallin et al.   Cancer Discovery

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

PIK3CA mutation and colorectal cancer precision medicine

(2017) Tsuyoshi Hamada et al.   Oncotarget

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

(2016) D. P. Modest et al.   ANNALS OF ONCOLOGY

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

(2016) P. Lito et al.   SCIENCE

Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

(2015) Robert J. Mayer et al.   NEW ENGLAND JOURNAL OF MEDICINE

KRAS Protein Stability Is Regulated through SMURF2: UBCH5 Complex-Mediated β-TrCP1 Degradation

(2015) Shirish Shukla et al.   NEOPLASIA

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

(2013) Jonathan M. Ostrem et al.   NATURE

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery